In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free ...

The MEDIOLA trial evaluated olaparib (Lynparza) and durvalumab (Imfinzi) with or without bevacizumab in recurrent ovarian cancer and showed a 34% response rate with the PARP inhibitor and the PD-L1 ...

Zejula (niraparib) was approved for the treatment of patients with newly diagnosed ovarian cancer whose disease responded to chemotherapy. Patients can receive Zejula for up to three years after ...

AstraZeneca has been boosted by results from ASCO which show its Lynparza could expand its use beyond ovarian cancer. Results from a phase 3 trial presented today showed that patients treated with ...

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer. Results from the PAOLA-1 study showed ...

The PARP inhibitor Zejula (niraparib) can be used for recently-diagnosed advanced ovarian cancer that has responded (complete or partial response) to platinum-based chemotherapy. The PARP inhibitor ...

A mini-oral presentation at ESMO will highlight first results from the endometrial and ovarian cancer cohorts of the ... to develop and commercialize LYNPARZA ® (olaparib), and collaborating ...

Lynparza is approved for four cancer types — ovarian, breast, prostate and pancreatic. The profit-sharing deal between AstraZeneca and Merck was inked in 2017. Apart from Lynparza, the Merck ...